Wockhardt's Q1 FY27 shows a dramatic profit turnaround, yet a sequential margin dip hints at costs ahead for its landmark antibiotic launch.
Wockhardt swung to a ₹107 crore profit in Q1 FY27 from a loss a year ago, driven by 26% revenue growth and a 112% surge in biotech. However, profit margins contracted from the previous quarter as the company prepares for the costly launch of its novel antibiotic Zaynich.
For Wockhardt, the first quarter of FY27 was a story of two recoveries. The headline is a clean escape from last year's deep loss, powered by a booming biotech division. Yet, the path forward is marked by a sequential profit dip, a sign of the investment phase beginning for its historic new antibiotic.
Revenue grew 25.9% year-on-year to ₹929 crore, while profit swung to ₹107 crore from a ₹108 crore loss. This turnaround is stark against the year-ago quarter, which was weighed down by a ₹97 crore exceptional impairment from exiting its US generics business, as reported by The Week. Strip that out, and the underlying recovery from a smaller loss is still solid, driven by operating leverage as expenses grew at less than half the rate of sales.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 929YoY +26% | 965 | 738 |
| Profit (₹ Cr) | 107YoY +199% | 164 | -108 |
| Net Profit Margin (%) | 11.5YoY +179% | 17.0 | -14.6 |
Sequentially, revenue dipped 3.7% and profit fell 34.8%. The net profit margin contracted 550 basis points from the March quarter's 17%. Reports from StockWatch suggest this is typical post-year-end normalization, not a business deterioration. The real story is the year-on-year climb.
The core driver was the biotech segment, which grew 112% year-on-year to ₹236 crore, according to CNBC-TV18. Emerging markets, particularly in Latin America and Asia, led this charge with 146% growth, fueled by insulin products and new distribution deals. The UK and Ireland regions also posted steady growth, while India's branded business rose 21%.
This performance underscores a strategic shift. Wockhardt is harvesting years of investment, with its vertically integrated biotech infrastructure now delivering high-margin sales. It provides the cash flow to fund the next ambitious chapter.
Live Chart
· WOCKPHARMA
(BSE)
ISIN: INE049B01025
The quarter's margin contraction offers a first glimpse of that next chapter. In May 2026, Wockhardt received US FDA approval for Zaynich, the first India-discovered novel antibiotic to achieve this milestone. While not yet launched, management has flagged that pre-launch and commercialization costs will create a minor negative bottom-line impact over the next 12-18 months, as noted in public reports.
The company is building a specialized US team and scaling up for a launch targeted for early 2027. The market potential is vast, with peak sales guidance of $1.5-2 billion, but the near-term financial picture will reflect these investments. The sequential profit dip from Q4's seasonally strong performance may be a pattern as these costs ramp up.
Key Points
The quarter confirms the operating turnaround is real. The base business, especially biotech, is generating strong growth and cash. This foundation is critical because it must now carry the company through the costly commercialization of Zaynich.
Investors are being asked to pay for a future that is still being written. The current valuation embeds immense expectations for Zaynich's success. The next few quarters will be a balancing act: demonstrating that the core business's momentum can offset the planned investment drag, while hitting launch milestones for the antibiotic without delays or cost overruns. Execution on both fronts will decide if the premium is justified.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.